NCT06753006 Research on the Effectiveness of Neurorehabilitation After Stroke
| NCT ID | NCT06753006 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neurotechnika |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-08-27 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2024-08-27 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial aims to investigate the effectiveness of a novel neurorehabilitation technology for treating stroke in adults. The study will evaluate a simulator that combines robotic orthosis, a non-invasive brain-computer interface (BCI), and a virtual reality (VR) display. The goal of this trial is to advance stroke rehabilitation by exploring the potential benefits of these cutting-edge technologies. Key Research Questions: Efficacy: Does the new simulator significantly improve arm function compared to standard rehabilitation techniques? BCI Technology: Which approach - motor imagery of only the paretic arm or both the paretic and healthy arm - yields greater functional improvements? VR Contribution: How does the integration of VR enhance rehabilitation outcomes? Safety and Tolerability: What potential side effects or adverse events may arise from using the new simulator? Participants who have suffered a stroke will undergo a standard rehabilitation course, during which 10-12 sessions will take place using the innovative simulator: a robotic device moves a patient's paralyzed arm at the command of a non-invasive brain-computer interface to perform a game task resembling real-life activities, augmented by a virtual reality display. Researchers will assess the impact of the new technology on arm function to determine its efficacy in promoting recovery.
Eligibility Criteria
Inclusion Criteria: * Signed written informed consent. * Age 18 to 80 years at the time of stroke onset. * Early rehabilitation period (up to 6 months post-stroke). * Diagnosis of acute cerebrovascular accident confirmed by MRI or CT. * Upper limb paresis severity between 0 and 3 on the 6-point Medical Research Council (MRC) muscle strength scale. * Ability and willingness to comply with the study protocol. * Demonstrated motivation for rehabilitation. Exclusion Criteria: * Montreal Cognitive Assessment scale (MoCA) score less than 10 points. * Hamilton Depression Rating Scale (Ham-D) score greater than 18 points. * Modified Rankin Scale (mRS) score greater than 4 points. * Pre-existing conditions that cause decreased muscle strength or increased muscle tone in the upper limbs (e.g., cerebral palsy, traumatic brain injury) or rigidity (e.g., Parkinson's disease, contractures). * Advanced arthritis or significant limitation of upper limb range of motion. * Absence of part of the upper limb due to amputation for any reason. * Any medical condition that may affect the conduct of the study or patient safety (e.g., mental illness). * Alcohol abuse or recreational drug use within the 12 months preceding the study. * Use of experimental medications or medical devices within the 30 days preceding the study. * Inability to comply with research procedures, as determined by the researcher. * The severity of the patient's condition, based on neurological or physical status, does not permit full rehabilitation. * Visual acuity less than 0.2 in the weakest eye according to the Sivtsev visual acuity chart. * Unstable angina and/or heart attack within the 30 days preceding the study. * Recurrent stroke. * Uncontrolled arterial hypertension. * Ataxia. * Presence of a pacemaker and/or other implanted electronic devices. * Use of muscle relaxants. * Peripheral neuropathy. * Coexisting diseases in an exacerbation or decompensated stage requiring active treatment. * Allergic reactions or other skin lesions at the EEG electrode application sites at the time of the study. * Acute urinary tract infections. * Acute thrombophlebitis. * Any form of epilepsy. * Benign and malignant neoplasms.
Contact & Investigator
Alexander Zakharov, Ph.D.
PRINCIPAL INVESTIGATOR
Samara State Medical University
Frequently Asked Questions
Who can join the NCT06753006 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06753006 currently recruiting?
Yes, NCT06753006 is actively recruiting participants. Contact the research team at vb@ntech.team for enrollment information.
Where is the NCT06753006 trial being conducted?
This trial is being conducted at Samara, Russia.
Who is sponsoring the NCT06753006 clinical trial?
NCT06753006 is sponsored by Neurotechnika. The principal investigator is Alexander Zakharov, Ph.D. at Samara State Medical University. The trial plans to enroll 44 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.